KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?

Abstract excerpt

KRAS mutations are among the most commonly occurring mutations in cancer. After being deemed undruggable for decades, KRAS G12C specific inhibitors showed that small molecule inhibitors can be developed against this notorious target. At the same time, there is still no agent that could target KRAS G12D which is the most common KRAS mutation and is found in the majority of KRAS-mutated pancreatic tumors....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Biochemical and Molecular Research
• Share to Cancer Research and Treatments
• Share to Pancreatic and Hepatic Oncology Research